{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:37:33Z","timestamp":1790797053430,"version":"4.1.0"},"reference-count":248,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Prolactinomas (PRLomas) constitute approximately half of all pituitary adenomas and approximately one-fifth of them are diagnosed in males. The clinical presentation of PRLomas results from direct prolactin (PRL) action, duration and severity of hyperprolactinemia, and tumor mass effect. Male PRLomas, compared to females, tend to be larger and more invasive, are associated with higher PRL concentration at diagnosis, present higher proliferative potential, are more frequently resistant to standard pharmacotherapy, and thus may require multimodal approach, including surgical resection, radiotherapy, and alternative medical agents. Therefore, the management of PRLomas in men is challenging in many cases. Additionally, hyperprolactinemia is associated with a significant negative impact on men\u2019s health, including sexual function and fertility potential, bone health, cardiovascular and metabolic complications, leading to decreased quality of life. In this review, we highlight the differences in pathogenesis, clinical presentation and treatment of PRLomas concerning the male sex.<\/jats:p>","DOI":"10.3389\/fendo.2024.1338345","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T09:42:41Z","timestamp":1706866961000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment"],"prefix":"10.3389","volume":"15","author":[{"given":"Lukasz","family":"Dzialach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Sobolewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Zak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wioleta","family":"Respondek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemys\u0142aw","family":"Witek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2020.04.002","article-title":"The epidemiology of pituitary adenomas","volume":"49","author":"Daly","year":"2020","journal-title":"Endocrinol Metab Clinics North America"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20412","article-title":"The prevalence of pituitary adenomas: A systematic review","volume":"101","author":"Ezzat","year":"2004","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00234-015-1519-3","article-title":"Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference","volume":"57","author":"Kreutz","year":"2015","journal-title":"Neuroradiology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.82.7.4088","article-title":"Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study","volume":"82","author":"Delgrange","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1055\/s-0037-1615748","article-title":"Comparison of male and female prolactinoma patients requiring surgical intervention","volume":"79","author":"Yoo","year":"2018","journal-title":"J Neurol Surg B Skull Base"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0013","article-title":"Therapy of endocrine disease: the challenges in managing giant prolactinomas","volume":"170","author":"Maiter","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00234-002-0774-2","article-title":"Gender-related differences in prolactin secretion in pituitary prolactinomas","volume":"44","author":"Nishioka","year":"2002","journal-title":"Neuroradiology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000495775","article-title":"Management of dopamine agonist-resistant prolactinoma","volume":"109","author":"Maiter","year":"2019","journal-title":"Neuroendocrinology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0012","article-title":"Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients","volume":"160","author":"Delgrange","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-019-01009-y","article-title":"Prolactinomas in males: any differences","volume":"23","author":"Duskin-Bitan","year":"2020","journal-title":"Pituitary"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2021.03.007","article-title":"Prevalence of hyperprolactinemia and clinically apparent prolactinomas in men undergoing fertility evaluation","volume":"159","author":"Ambulkar","year":"2022","journal-title":"Urology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s0090-3019(03)00012-0","article-title":"Growth potential of prolactinomas in men: is it really different from women","volume":"59","author":"Nishioka","year":"2003","journal-title":"Surg Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2012.04351.x","article-title":"Prolactinomas in men: a multicentre and retrospective analysis of treatment outcome","volume":"77","author":"Iglesias","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1055\/a-0752-0741","article-title":"Giant prolactinoma in men: clinical features and therapeutic outcomes","volume":"50","author":"Iglesias","year":"2018","journal-title":"Horm Metab Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11102-019-00997-1","article-title":"Pathology of prolactinomas: any predictive value","volume":"23","author":"Lopes","year":"2020","journal-title":"Pituitary"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-01962-5","article-title":"Hyperprolactinemia diagnosis in elderly men: a cohort of 28 patients over 65 years","volume":"65","author":"Shimon","year":"2019","journal-title":"Endocrine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-010-0251-6","article-title":"Anemia in a cohort of men with macroprolactinomas: increase in hemoglobin levels follows prolactin suppression","volume":"14","author":"Shimon","year":"2011","journal-title":"Pituitary"},{"key":"B20","article-title":"Gender-related differences in prolactinomas","volume":"26","author":"Schaller","year":"2005","journal-title":"A clinicopathological study. Neuro Endocrinol Lett"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-015-0006-4","article-title":"Management of macroprolactinomas","volume":"1","author":"Tirosh","year":"2015","journal-title":"Clin Diabetes Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/BF03349742","article-title":"Prolactinoma in 53 men: clinical characteristics and modes of treatment (male prolactinoma)","volume":"18","author":"Berezin","year":"1995","journal-title":"J Endocrinol Invest"},{"key":"B23","article-title":"Prolactin-secreting pituitary adenomas in males: transsphenoidal microsurgical treatment","volume":"122","author":"Serri","year":"1980","journal-title":"Can Med Assoc J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-015-0791-7","article-title":"Giant prolactinomas: are they really different from ordinary macroprolactinomas","volume":"52","author":"Espinosa","year":"2016","journal-title":"Endocrine"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0537","article-title":"Incidence of pituitary adenomas in Northern Finland in 1992-2007","volume":"95","author":"Raappana","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-0177","article-title":"Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia","volume":"94","author":"Kars","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13498","article-title":"Males with prolactinoma are at increased risk of incident cardiovascular disease","volume":"88","author":"Toulis","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2010.150","article-title":"BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists","volume":"19","author":"dos Santos Silva","year":"2011","journal-title":"Obes (Silver Spring)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1015520","article-title":"Metabolic effects of prolactin","volume":"13","author":"Pirchio","year":"2022","journal-title":"Front Endocrinol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1385\/ENDO:20:1-2:75","article-title":"Hyperprolactinemia in men: clinical and biochemical features and response to treatment","volume":"20","author":"De Rosa","year":"2003","journal-title":"Endocrine"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14541","article-title":"Long-term response to cabergoline and multi-modal treatment in men with macroprolactinoma: Does size really matter","volume":"95","author":"Rudman","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12060796","article-title":"Hypogonadism in male patients with pituitary adenoma and its related mechanism: a review of literature","volume":"12","author":"Yan","year":"2022","journal-title":"Brain Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9050494","article-title":"Pituitary adenomas: from diagnosis to therapeutics","volume":"9","author":"Banskota","year":"2021","journal-title":"Biomedicines"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4103\/0974-1208.86094","article-title":"Hyperprolactinemia: An often missed cause of male infertility","volume":"4","author":"Singh","year":"2011","journal-title":"J Hum Reprod Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-011-9462-5","article-title":"Vertebral fractures in males with prolactinoma","volume":"39","author":"Mazziotti","year":"2011","journal-title":"Endocrine"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2000.00902.x","article-title":"Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization","volume":"52","author":"Colao","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12902-021-00733-6","article-title":"Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study","volume":"21","author":"Posawetz","year":"2021","journal-title":"BMC Endocr Disord"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345636","article-title":"Body fat in men with prolactinoma","volume":"31","author":"Naliato","year":"2008","journal-title":"J Endocrinol Invest"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B40","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-21-0977","article-title":"Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors","volume":"186","author":"Cozzi","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-019-00971-x","article-title":"Role of gamma knife radiosurgery in the treatment of prolactinomas","volume":"22","author":"Je\u017ekov\u00e1","year":"2019","journal-title":"Pituitary"},{"key":"B42","doi-asserted-by":"publisher","first-page":"101269","DOI":"10.1016\/j.beem.2019.04.003","article-title":"The risk\/benefit ratio of radiotherapy in pituitary tumors","volume":"33","author":"Minniti","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-011-0348-6","article-title":"Radiotherapy for prolactin-secreting pituitary tumors","volume":"15","author":"Sheplan Olsen","year":"2012","journal-title":"Pituitary"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.924884","article-title":"Gamma knife radiosurgery (GKRS) for patients with prolactinomas: long-term results from a single-center experience","volume":"26","author":"Li","year":"2020","journal-title":"Med Sci Monit"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1668","article-title":"High prevalence of pituitary adenomas: a cross-sectional study in the province of Li\u00e8ge, Belgium","volume":"91","author":"Daly","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1590\/2359-3997000000195","article-title":"Incidence and prevalence of clinically relevant pituitary adenomas: retrospective cohort study in a Health Management Organization in Buenos Aires, Argentina","volume":"60","author":"Day","year":"2016","journal-title":"Arch Endocrinol Metab"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0189","article-title":"The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study","volume":"173","author":"Agustsson","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03667.x","article-title":"Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)","volume":"72","author":"Fernandez","year":"2010","journal-title":"Clin Endocrinol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0503","article-title":"Giant prolactinomas in women","volume":"170","author":"Delgrange","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1480325","article-title":"Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia","volume":"148","author":"Colao","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocrine Rev"},{"key":"B52","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12902-020-0543-4","article-title":"Predictors of dopamine agonist resistance in prolactinoma patients","volume":"20","author":"Vermeulen","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-021-01184-x","article-title":"Management of prolactinomas in children and adolescents; which factors define the response to treatment","volume":"25","author":"Alikasifoglu","year":"2022","journal-title":"Pituitary"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.83.8.5001","article-title":"Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up","volume":"83","author":"Colao","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"B55","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1159\/000236081","article-title":"Prolactinoma in children and adolescents","volume":"72","author":"Fideleff","year":"2009","journal-title":"Horm Res Paediatr"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3670","article-title":"Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients","volume":"100","author":"Salenave","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-017-3042-5","article-title":"Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis","volume":"177","author":"Hoffmann","year":"2018","journal-title":"Eur J Pediatr"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13064","article-title":"Epidemiology and radiological geometric assessment of pituitary macroadenomas: population-based study","volume":"85","author":"Gruppetta","year":"2016","journal-title":"Clin Endocrinol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-023-01337-0","article-title":"Giant prolactinomas, a detailed analysis of 196 adult cases","volume":"26","author":"Lisa","year":"2023","journal-title":"Pituitary"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12242","article-title":"Giant prolactinomas: the therapeutic approach","volume":"79","author":"Moraes","year":"2013","journal-title":"Clin Endocrinol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2021.104080","article-title":"Prolactinomas","volume":"50","author":"Wildemberg","year":"2021","journal-title":"Presse Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00550-w","article-title":"Aggressive pituitary tumours and pituitary carcinomas","volume":"17","author":"Raverot","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40478-015-0229-8","article-title":"Histological criteria for atypical pituitary adenomas \u2013 data from the German pituitary adenoma registry suggests modifications","volume":"3","author":"Miermeister","year":"2015","journal-title":"Acta Neuropathol Commun"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0440","article-title":"Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients","volume":"187","author":"Burman","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0933","article-title":"Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016","volume":"178","author":"McCormack","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-021-02633-0","article-title":"The clinical aspects of pituitary tumour genetics","volume":"71","author":"D\u00e9nes","year":"2021","journal-title":"Endocrine"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1055\/a-1143-5930","article-title":"Clinical and molecular update on genetic causes of pituitary adenomas","volume":"52","author":"Vasilev","year":"2020","journal-title":"Horm Metab Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1159\/000318494","article-title":"Gender differences in macroprolactinomas: study of clinical features, outcome of patients and ki-67 expression in tumor tissue","volume":"38","author":"Fainstein Day","year":"2010","journal-title":"Front Horm Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-005-0498-2","article-title":"Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance","volume":"147","author":"Delgrange","year":"2005","journal-title":"Acta Neurochir (Wien)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1159\/000499382","article-title":"Clinical, pathological, and molecular factors of aggressiveness in lactotroph tumours","volume":"109","author":"Trouillas","year":"2019","journal-title":"Neuroendocrinology"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.4065\/73.11.1046","article-title":"Prolactinomas in male and female patients: a comparative clinicopathologic study","volume":"73","author":"Calle-Rodrigue","year":"1998","journal-title":"Mayo Clinic Proc"},{"key":"B72","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1530\/EJE-14-0990","article-title":"Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth","volume":"172","author":"Delgrange","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00706","article-title":"Sex-related differences in lactotroph tumor aggressiveness are associated with a specific gene-expression signature and genome instability","volume":"9","author":"Wierinckx","year":"2018","journal-title":"Front Endocrinol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-020-01029-z","article-title":"Expression patterns of ER\u03b166 and its novel variant isoform ER\u03b136 in lactotroph pituitary adenomas and associations with clinicopathological characteristics","volume":"23","author":"Mahboobifard","year":"2020","journal-title":"Pituitary"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.78.1.8288720","article-title":"In situ hybridization study of estrogen receptor messenger ribonucleic acid in human adenohypophysial cells and pituitary adenomas","volume":"78","author":"Stefaneanu","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)34893-2","article-title":"Estradiol regulates the transcription of the prolactin gene","volume":"257","author":"Maurer","year":"1982","journal-title":"J Biol Chem"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.75.12.5946","article-title":"Estrogen control of prolactin synthesis","volume":"75","author":"Lieberman","year":"1978","journal-title":"vitro. Proc Natl Acad Sci USA"},{"key":"B78","article-title":"Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration","volume":"118","author":"Kovacs","year":"1994","journal-title":"A morphologic study. Arch Pathol Lab Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy108","article-title":"The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment","volume":"141","author":"Nota","year":"2018","journal-title":"Brain"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2018-0101","article-title":"Prolactin levels do not rise among transgender women treated with estradiol and spironolactone","volume":"24","author":"Bisson","year":"2018","journal-title":"Endocrine Pract"},{"key":"B81","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/s0010-7824(98)00069-9","article-title":"Two-year treatment with oral contraceptives in hyperprolactinemic patients","volume":"58","author":"Testa","year":"1998","journal-title":"Contraception"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(82)90641-x","article-title":"Oral contraceptives and prolactinomas: a case-control study","volume":"143","author":"Maheux","year":"1982","journal-title":"Am J Obstet Gynecol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-10-0016","article-title":"Enhanced LH action in transgenic female mice expressing hCG\u03b2-subunit induces pituitary prolactinomas; the role of high progesterone levels","volume":"17","author":"Ahtiainen","year":"2010","journal-title":"Endocrine-Related Cancer"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1210\/en.2004-1276","article-title":"Progesterone antagonizes the permissive action of estradiol on tumor necrosis factor-\u03b1-induced apoptosis of anterior pituitary cells","volume":"146","author":"Candolfi","year":"2005","journal-title":"Endocrinology"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1210\/en.2002-220421","article-title":"Ovarian dependence for pituitary tumorigenesis in D2 dopamine receptor-deficient mice","volume":"143","author":"Hentges","year":"2002","journal-title":"Endocrinology"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1210\/en.2002-220490","article-title":"Reproductive disturbances, pituitary lactotrope adenomas, and mammary gland tumors in transgenic female mice producing high levels of human chorionic gonadotropin","volume":"143","author":"Rulli","year":"2002","journal-title":"Endocrinology"},{"key":"B87","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1530\/ERC-18-0409","article-title":"mPRs represent a novel target for PRL inhibition in experimental prolactinomas","volume":"26","author":"Camilletti","year":"2019","journal-title":"Endocrine-Related Cancer"},{"key":"B88","doi-asserted-by":"publisher","first-page":"e12614","DOI":"10.1111\/jne.12614","article-title":"D\u00edaz-Torga G. Participation of membrane progesterone receptor \u03b1 in the inhibitory effect of progesterone on prolactin secretion","volume":"30","author":"Camilletti","year":"2018","journal-title":"J Neuroendocrinol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(00)80351-7","article-title":"Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice","volume":"19","author":"Kelly","year":"1997","journal-title":"Neuron"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2019.108496","article-title":"New insights into progesterone actions on prolactin secretion and prolactinoma development","volume":"152","author":"Camilletti","year":"2019","journal-title":"Steroids"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1210\/en.2005-0430","article-title":"Dopamine, dopamine D2 receptor short isoform, transforming growth factor (TGF)-beta1, and TGF-beta type II receptor interact to inhibit the growth of pituitary lactotropes","volume":"146","author":"Sarkar","year":"2005","journal-title":"Endocrinology"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-16-0371","article-title":"Sex differences in the development of prolactinoma in mice overexpressing hCG\u03b2: role of TGF\u03b21","volume":"232","author":"Faraoni","year":"2017","journal-title":"J Endocrinol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.yfrne.2017.10.003","article-title":"Sex differences in the pituitary TGF\u03b21 system: The role of TGF\u03b21 in prolactinoma development","volume":"50","author":"Recouvreux","year":"2018","journal-title":"Front Neuroendocrinol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1210\/en.2010-1464","article-title":"Active and total transforming growth factor-\u03b21 are differentially regulated by dopamine and estradiol in the pituitary","volume":"152","author":"Recouvreux","year":"2011","journal-title":"Endocrinology"},{"key":"B95","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.mce.2014.12.024","article-title":"The role of TGF-\u03b2\/Smad signaling in dopamine agonist-resistant prolactinomas","volume":"402","author":"Li","year":"2015","journal-title":"Mol Cell Endocrinol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2018.07.024","article-title":"Role of TGF-\u03b21\/Smad3-mediated fibrosis in drug resistance mechanism of prolactinoma","volume":"1698","author":"Hu","year":"2018","journal-title":"Brain Res"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-15-0451","article-title":"The pituitary TGF\u03b21 system as a novel target for the treatment of resistant prolactinomas","volume":"228","author":"Recouvreux","year":"2016","journal-title":"J Endocrinol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/BF02738884","article-title":"Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas","volume":"10","author":"Lloyd","year":"1999","journal-title":"Endocr Pathol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-014-0056-y","article-title":"The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy","volume":"33","author":"Wang","year":"2014","journal-title":"J Exp Clin Cancer Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqac108","article-title":"Sex-specific regulation of prolactin secretion by pituitary bradykinin receptors","volume":"163","author":"Abeledo-MaChado","year":"2022","journal-title":"Endocrinology"},{"key":"B102","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1038\/s41467-020-16052-8","article-title":"Somatic SF3B1 hotspot mutation in prolactinomas","volume":"11","author":"Li","year":"2020","journal-title":"Nat Commun"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvad114","article-title":"Prevalence and clinical correlations of SF3B1 variants in lactotroph tumours","volume":"189","author":"Simon","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"E2203","DOI":"10.3390\/jcm8122203","article-title":"Hyperprolactinaemia","volume":"8","author":"Samperi","year":"2019","journal-title":"J Clin Med"},{"key":"B105","unstructured":"Hyperprolactinemia\n            GlezerA\n            BronsteinMD\n          South Dartmouth (MAMDText.com, IncEndotext2000"},{"key":"B106","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000499694","article-title":"Pitfalls in the diagnostic evaluation of hyperprolactinemia","volume":"109","author":"Vilar","year":"2019","journal-title":"Neuroendocrinology"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0b013e32834bdf01","article-title":"Prolactin in men\u2019s health and disease","volume":"21","author":"Bolyakov","year":"2011","journal-title":"Curr Opin Urol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4730-6","article-title":"Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research","volume":"234","author":"Grigg","year":"2017","journal-title":"Psychopharmacol (Berl)"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-021-02624-1","article-title":"True hyperprolactinemia in men without visible pituitary adenoma","volume":"72","author":"Shimon","year":"2021","journal-title":"Endocrine"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1732490","article-title":"Prevalence of macroprolactinemia in people detected to have hyperprolactinemia","volume":"13","author":"Sharma","year":"2021","journal-title":"J Lab Physicians"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030979","article-title":"Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis","volume":"89","author":"Colao","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-022-01246-8","article-title":"Prolactin immunoassay: does the high-dose hook effect still exist","volume":"25","author":"Raverot","year":"2022","journal-title":"Pituitary"},{"key":"B113","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1530\/EDM-16-0069","article-title":"Late presentation of acromegaly in medically controlled prolactinoma patients","volume":"2016","author":"Manuylova","year":"2016","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1590\/s0004-282x2006000500026","article-title":"[IGF-1 plasma levels evaluation in prolactinoma]","volume":"64","author":"Zylberberg","year":"2006","journal-title":"Arq Neuropsiquiatr"},{"key":"B115","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11102-019-01001-6","article-title":"Magnetic resonance imaging in\u202fthe management of prolactinomas; a review of the evidence","volume":"23","author":"Varlamov","year":"2020","journal-title":"Pituitary"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1227\/00006123-199310000-00008","article-title":"Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings","volume":"33","author":"Knosp","year":"1993","journal-title":"Neurosurgery"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00439","article-title":"Prolactinomas: prognostic factors of early remission after transsphenoidal surgery","volume":"11","author":"Zielinski","year":"2020","journal-title":"Front Endocrinol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-018-0877-3","article-title":"Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas","volume":"21","author":"Dogansen","year":"2018","journal-title":"Pituitary"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-018-1765-3","article-title":"T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists","volume":"63","author":"Burlacu","year":"2019","journal-title":"Endocrine"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153604","article-title":"Update in pathogenesis, diagnosis, and therapy of prolactinoma","volume":"14","author":"Fukuhara","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-017-3302-1","article-title":"Clinical characteristics of pituitary adenomas with radiological calcification","volume":"159","author":"Ogiwara","year":"2017","journal-title":"Acta Neurochir"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.123573","article-title":"Pituitary calcification masquerading as pituitary apoplexy","volume":"17","author":"Garg","year":"2013","journal-title":"Indian J Endocrinol Metab"},{"key":"B123","article-title":"[Pituitary adenoma calcification]","volume":"38","author":"Kurisaka","year":"1986","journal-title":"No To Shinkei"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1677686","article-title":"CSF rhinorrhea following medical treatment for prolactinoma: management and challenges","volume":"80","author":"Arimappamagan","year":"2019","journal-title":"J Neurol Surg B Skull Base"},{"key":"B125","article-title":"Pituitary adenomas: an overview","volume":"88","author":"Lake","year":"2013","journal-title":"Am Fam Physician"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0941","article-title":"Reduced sleep quality and depression associate with decreased quality of life in patients with pituitary adenomas","volume":"172","author":"Leistner","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13915","article-title":"Quality of life is significantly impaired in both secretory and non-functioning pituitary adenomas","volume":"90","author":"Vega-Beyhart","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0041","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease","volume":"177","author":"Webb","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0259","article-title":"Quality of life is decreased in female patients treated for microprolactinoma","volume":"157","author":"Kars","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1023\/a:1025377816769","article-title":"Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function","volume":"5","author":"Sibal","year":"2002","journal-title":"Pituitary"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-014-0563-z","article-title":"Hypopituitarism patterns and prevalence among men with macroprolactinomas","volume":"18","author":"Tirosh","year":"2015","journal-title":"Pituitary"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2016.01.029","article-title":"Hypopituitarism patterns among adult males with prolactinomas","volume":"144","author":"Peng","year":"2016","journal-title":"Clin Neurol Neurosurg"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12124","article-title":"Does hypopituitarism recover when macroprolactinomas are treated with cabergoline","volume":"79","author":"Karavitaki","year":"2013","journal-title":"Clin Endocrinol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.9.6798","article-title":"Primary medical therapy of micro- and macroprolactinomas in men*","volume":"85","author":"Pinzone","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02461.x","article-title":"The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males","volume":"64","author":"Rosa","year":"2006","journal-title":"Clin Endocrinol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa650","article-title":"Predictors of chronic LH-testosterone axis suppression in male macroprolactinomas with normoprolactinemia on cabergoline","volume":"105","author":"Sehemby","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001431","article-title":"Prolactin-to-testosterone ratio predicts pituitary abnormalities in mildly hyperprolactinemic men with symptoms of hypogonadism","volume":"205","author":"Naelitz","year":"2021","journal-title":"J Urol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-013-0497-x","article-title":"Male prolactinomas presenting with normal testosterone levels","volume":"17","author":"Shimon","year":"2014","journal-title":"Pituitary"},{"key":"B139","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1038\/s41598-021-84606-x","article-title":"Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas","volume":"11","author":"Andereggen","year":"2021","journal-title":"Sci Rep"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-022-01259-3","article-title":"Predicting hypogonadotropic hypogonadism persistence in male macroprolactinoma","volume":"25","author":"Rudman","year":"2022","journal-title":"Pituitary"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab048.1289","article-title":"Recovery of male hypogonadism following successful treatment of prolactinoma: the experience of an integrated health network","volume":"5","author":"Voica","year":"2021","journal-title":"J Endocrine Soc"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-022-01242-y","article-title":"Proportion and predictors of Hypogonadism Recovery in Men with Macroprolactinomas treated with dopamine agonists","volume":"25","author":"Al Dahmani","year":"2022","journal-title":"Pituitary"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1982.tb03159.x","article-title":"PULSATILE GONADOTROPHIN SECRETION IN HYPERPROLACTINAEMIC AMENORRHOEA AND THE RESPONSE TO BROMOCRIPTINE THERAPY","volume":"16","author":"Moult","year":"1982","journal-title":"Clin Endocrinol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-101-6-783","article-title":"Bromocriptine treatment of prolactin-secreting pituitary adenomas may restore pituitary function","volume":"101","author":"Warfield","year":"1984","journal-title":"Ann Intern Med"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2000.01137.x","article-title":"Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas","volume":"53","author":"George","year":"2000","journal-title":"Clin Endocrinol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2003.98.5.0974","article-title":"Anemia, testosterone, and pituitary adenoma in men","volume":"98","author":"Ellegala","year":"2003","journal-title":"J Neurosurg"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1111\/andr.13428","article-title":"Hemoglobin decline as a signal for hyperprolactinemia onset prior to prolactinoma diagnosis in hypogonadal men","volume":"11","author":"Rudman","year":"2023","journal-title":"Andrology"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1007\/BF00273860","article-title":"Severe hyperprolactinaemia is associated with decreased insulin binding in vitro and insulin resistance in vivo","volume":"28","author":"Schernthaner","year":"1985","journal-title":"Diabetologia"},{"key":"B149","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/BF00745135","article-title":"Prolactin: A diabetogenic hormone","volume":"13","author":"Landgraf","year":"1977","journal-title":"Diabetologia"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2826.2003.01092.x","article-title":"Changes in Agouti-Related Peptide During the Ring Dove Breeding Cycle in Relation to Prolactin and Parental Hyperphagia: AGRP, prolactin, and hyperphagia in breeding doves","volume":"15","author":"Strader","year":"2003","journal-title":"J Neuroendocrinol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1002320","article-title":"Metabolic effects of prolactin and the role of dopamine agonists: A review","volume":"13","author":"Kirsch","year":"2022","journal-title":"Front Endocrinol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000371851","article-title":"Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas","volume":"101","author":"Auriemma","year":"2015","journal-title":"Neuroendocrinology"},{"key":"B153","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1530\/eje.0.1470077","article-title":"Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine","volume":"147","author":"Doknic","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13098-015-0094-4","article-title":"Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline","volume":"7","author":"Pala","year":"2015","journal-title":"Diabetol Metab Syndr"},{"key":"B155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-12114-7_1","article-title":"\u201cProlactin (PRL) in adipose tissue: regulation and functions.,\u201d","volume-title":"Recent advances in prolactin research. Advances in experimental medicine and biology","author":"Ben-Jonathan","year":"2015"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.4103\/njcp.njcp_178_20","article-title":"Is idiopathic mild hyperprolactinemia a cardiovascular risk factor","volume":"24","author":"Koca","year":"2021","journal-title":"Niger J Clin Pract"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3390\/nu14245369","article-title":"Increased thoracic fluid as the most distinctive cardiovascular hemodynamic alteration in men with prolactinoma","volume":"14","author":"Jurek","year":"2022","journal-title":"Nutrients"},{"key":"B158","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1055\/a-0902-4439","article-title":"Cardiometabolic risk factors in men with elevated macroprolactin content: a pilot study","volume":"129","author":"Krysiak","year":"2021","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B159","doi-asserted-by":"publisher","first-page":"e002640","DOI":"10.1161\/JAHA.115.002640","article-title":"Association between prolactin and incidence of cardiovascular risk factors in the framingham heart study","volume":"5","author":"Therkelsen","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00005","article-title":"Pituitary diseases and bone","volume":"39","author":"Mazziotti","year":"2018","journal-title":"Endocr Rev"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.83.3.4674","article-title":"Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males","volume":"83","author":"Di Somma","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1055\/a-0630-1529","article-title":"Relation of RANKL and OPG levels with bone resorption in patients with acromegaly and prolactinoma","volume":"50","author":"Ozer","year":"2018","journal-title":"Horm Metab Res"},{"key":"B163","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.wneu.2016.10.059","article-title":"Long-term follow-up of primary medical versus surgical treatment of prolactinomas in men: effects on hyperprolactinemia, hypogonadism, and bone health","volume":"97","author":"Andereggen","year":"2017","journal-title":"World Neurosurg"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.4103\/ijabmr.IJABMR_323_19","article-title":"Status of serum prolactin levels among male cohort in infertile couples","volume":"10","author":"Green","year":"2020","journal-title":"Int J Appl Basic Med Res"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/j.advms.2019.12.008","article-title":"Proven and unproven methods for diagnosis and treatment of infertility","volume":"65","author":"Szamatowicz","year":"2020","journal-title":"Adv Med Sci"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3390\/life12040570","article-title":"The fate of leydig cells in men with spermatogenic failure","volume":"12","author":"Adamczewska","year":"2022","journal-title":"Life (Basel)"},{"key":"B167","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.aju.2017.10.002","article-title":"Hyperprolactinaemia in male infertility: Clinical case scenarios","volume":"16","author":"Dabbous","year":"2018","journal-title":"Arab J Urol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1055\/a-0859-1144","article-title":"Unveiling the role of prolactin and its receptor in male reproduction","volume":"51","author":"Raut","year":"2019","journal-title":"Horm Metab Res"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.2147\/OAJU.S22916","article-title":"Abnormality of pituitary gonadal axis among Nigerian males with infertility: study of patterns and possible etiologic interrelationships","volume":"3","author":"Ozoemena","year":"2011","journal-title":"Open Access J Urol"},{"key":"B170","article-title":"[Correlation of serum prolactin, sperm count and motility. Prevalence of hyperprolactinemia in the infertile male]","volume":"43","author":"Soler Fern\u00e1ndez","year":"1990","journal-title":"Arch Esp Urol"},{"key":"B171","article-title":"Hormonal profile of men investigated for infertility at the University of Maiduguri in northern Nigeria","volume":"49","author":"Geidam","year":"2008","journal-title":"Singapore Med J"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3901043","article-title":"Hyperprolactinemia and sexual function in men: a short review","volume":"15","author":"Buvat","year":"2003","journal-title":"Int J Impot Res"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2008.01206.x","article-title":"Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction","volume":"6","author":"Corona","year":"2009","journal-title":"J Sex Med"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.3109\/01485018908986849","article-title":"Hypoprolactinemia as related to seminal quality and serum testosterone","volume":"23","author":"Gonzales","year":"1989","journal-title":"Arch Androl"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1002\/pros.2990240311","article-title":"Effect of prolactin on the prostate","volume":"24","author":"Costello","year":"1994","journal-title":"Prostate"},{"key":"B176","article-title":"Changes in prolactin receptor location in prostate tumors","volume":"74","author":"L\u00f3pez Fontana","year":"2021","journal-title":"Arch Esp Urol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7827-4-28","article-title":"Prostate response to prolactin in sexually active male rats","volume":"4","author":"Hernandez","year":"2006","journal-title":"Reprod Biol Endocrinol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrurol.2011.143","article-title":"Prolactin regulation of the prostate gland: a female player in a male game","volume":"8","author":"Goffin","year":"2011","journal-title":"Nat Rev Urol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-032055","article-title":"Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma","volume":"89","author":"Colao","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet0270","article-title":"Drug Insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia","volume":"2","author":"Goffin","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.35702\/onc.10013","article-title":"The suppression of prolactin is required for the treatment of advanced prostate cancer","volume":"2","author":"Costello","year":"2019","journal-title":"Oncogen (Westerville)"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-020-01039-x","article-title":"Do nothing but observe microprolactinomas: when and how to replace sex hormones","volume":"23","author":"Bonert","year":"2020","journal-title":"Pituitary"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2605","article-title":"Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas","volume":"95","author":"Ono","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12149","article-title":"A comparison between intensive and conventional cabergoline treatment of newly diagnosed patients with macroprolactinoma","volume":"79","author":"Rastogi","year":"2013","journal-title":"Clin Endocrinol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-1-33","article-title":"Treatment of hyperprolactinemia: a systematic review and meta-analysis","volume":"1","author":"Wang","year":"2012","journal-title":"Syst Rev"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342070-00003","article-title":"Clinical pharmacokinetics of cabergoline","volume":"42","author":"Del Dotto","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-010-0290-z","article-title":"Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis","volume":"14","author":"dos Santos Nunes","year":"2011","journal-title":"Pituitary"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1159\/000504000","article-title":"Treatment of pituitary and other tumours with cabergoline: new mechanisms and potential broader applications","volume":"110","author":"Lin","year":"2020","journal-title":"Neuroendocrinology"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1007\/BF03346388","article-title":"Diagnosis and management of hyperprolactinemia: Results of a Brazilian multicenter study with 1234 patients","volume":"31","author":"Vilar","year":"2008","journal-title":"J Endocrinol Invest"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz076","article-title":"Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors","volume":"105","author":"De Sousa","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02202","article-title":"Dopamine agonist-induced impulse control disorders in patients with prolactinoma: a cross-sectional multicenter study","volume":"104","author":"Dogansen","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01478-0","article-title":"Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study","volume":"44","author":"Beccuti","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-016-1088-1","article-title":"Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists","volume":"55","author":"De Sousa","year":"2017","journal-title":"Endocrine"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1403","article-title":"Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline","volume":"93","author":"Colao","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0231","article-title":"Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas","volume":"169","author":"Auriemma","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2012.04349.x","article-title":"No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma","volume":"77","author":"Halperin","year":"2012","journal-title":"Clin Endocrinol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-016-1120-5","article-title":"Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia","volume":"55","author":"Vroonen","year":"2017","journal-title":"Endocrine"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa882","article-title":"Incidence of cabergoline-associated valvulopathy in primary care patients with prolactinoma using hard cardiac endpoints","volume":"106","author":"Stiles","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa652","article-title":"Predictors of the response to dopaminergic therapy in patients with prolactinoma","volume":"105","author":"Hage","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B200","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11102-019-00987-3","article-title":"Dopamine agonist resistant prolactinomas: any alternative medical treatment","volume":"23","author":"Souteiro","year":"2020","journal-title":"Pituitary"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.82.3.3822","article-title":"Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment","volume":"82","author":"Colao","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-0236","article-title":"Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients","volume":"167","author":"Vroonen","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1159\/000126764","article-title":"Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas","volume":"60","author":"Caccavelli","year":"1994","journal-title":"Neuroendocrinology"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0656","article-title":"Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels","volume":"166","author":"Shimazu","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2902","article-title":"Filamin-A is essential for dopamine D2 receptor expression and signaling in tumorous lactotrophs","volume":"97","author":"Peverelli","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2008.1","article-title":"Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas","volume":"8","author":"Filopanti","year":"2008","journal-title":"Pharmacogenomics J"},{"key":"B207","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11102-016-0776-4","article-title":"Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment","volume":"20","author":"Bueno","year":"2017","journal-title":"Pituitary"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad020","article-title":"PRL-R variants are not only associated with prolactinomas but also with dopamine agonist resistance","volume":"108","author":"De Castro Moreira","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B209","doi-asserted-by":"publisher","first-page":"e8733","DOI":"10.1097\/MD.0000000000008733","article-title":"Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date","volume":"96","author":"Chen","year":"2017","journal-title":"Med (Baltimore)"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.700007","article-title":"Clinical efficacy of temozolomide and its predictors in aggressive pituitary tumors and pituitary carcinomas: a systematic review and meta-analysis","volume":"12","author":"Luo","year":"2021","journal-title":"Front Neurol"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03487.x","article-title":"Low O 6 -methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours","volume":"71","author":"McCormack","year":"2009","journal-title":"Clin Endocrinol"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.774686","article-title":"Early initiation of temozolomide therapy may improve response in aggressive pituitary adenomas","volume":"12","author":"Das","year":"2021","journal-title":"Front Endocrinol"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab190","article-title":"Temozolomide nonresponsiveness in aggressive prolactinomas and carcinomas: management and outcomes","volume":"6","author":"Das","year":"2022","journal-title":"J Endocrine Soc"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0279","article-title":"Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma","volume":"181","author":"Coopmans","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2018.07.013","article-title":"Pasireotide: A potential therapeutic alternative for resistant prolactinoma","volume":"80","author":"Lasolle","year":"2019","journal-title":"Annales d\u2019Endocrinologie"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02461","article-title":"Effect of everolimus in treatment of aggressive prolactin-secreting pituitary adenomas","volume":"104","author":"Zhang","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-023-01340-5","article-title":"The treatment of aggressive prolactinomas with everolimus","volume":"26","author":"Lin","year":"2023","journal-title":"Pituitary"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001532","article-title":"Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study","volume":"8","author":"Majd","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.576027","article-title":"Case report: A case of pituitary carcinoma treated with sequential dual immunotherapy and vascular endothelial growth factor inhibition therapy","volume":"11","author":"Lamb","year":"2020","journal-title":"Front Endocrinol"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa805","article-title":"EGFR\/ErbB2-targeting lapatinib therapy for aggressive prolactinomas","volume":"106","author":"Cooper","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-013-0093-x","article-title":"Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors","volume":"46","author":"Cooper","year":"2014","journal-title":"Endocrine"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.3390\/jpm10030088","article-title":"Immunotherapy in corticotroph and lactotroph aggressive tumors and carcinomas: two case reports and a review of the literature","volume":"10","author":"Duhamel","year":"2020","journal-title":"JPM"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0647","article-title":"Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study","volume":"187","author":"Ilie","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060828","article-title":"Treatment options for pancreatic neuroendocrine tumors","volume":"11","author":"Akirov","year":"2019","journal-title":"Cancers"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-021-01165-0","article-title":"Anastrozole as add-on therapy for cabergoline-resistant prolactin-secreting pituitary adenomas: real-life experience in male patients","volume":"24","author":"Ceccato","year":"2021","journal-title":"Pituitary"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.35171","article-title":"Effect of tamoxifen on the management of dopamine agonist-resistant prolactinomas: A systematic review","volume":"15","author":"Bazuhair","year":"2023","journal-title":"Cureus"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2556","article-title":"Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study","volume":"95","author":"Daly","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14706","article-title":"Molecular genetic testing in the management of pituitary disease","volume":"97","author":"Coopmans","year":"2022","journal-title":"Clin Endocrinol"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9062003","article-title":"Pituitary disease in AIP mutation-positive familial isolated pituitary adenoma (FIPA): A kindred-based overview","volume":"9","author":"Bilbao Garay","year":"2020","journal-title":"JCM"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1210\/JC.2015-2015","article-title":"Long-term natural course of pituitary tumors in patients with MEN1: results from the dutchMEN1 study group (DMSG)","volume":"100","author":"De Laat","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-0763","article-title":"Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don\u2019t forget MEN1 genetic analysis","volume":"168","author":"Cuny","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone therapy in men with hypogonadism: an endocrine society* Clinical practice guideline","volume":"103","author":"Bhasin","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0084","article-title":"Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment","volume":"161","author":"Ribeiro","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1227\/01.NEU.0000223445.22938.BD","article-title":"Gamma knife radiosurgery for medically and surgically refractory prolactinomas","volume":"59","author":"Pouratian","year":"2006","journal-title":"Neurosurgery"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvad044","article-title":"Radiotherapy in aggressive or dopamine agonists resistant prolactinomas; is it still worthwhile","volume":"188","author":"Niculescu","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"B236","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/4618664","article-title":"A retrospective trail investigating temozolomide neoadjuvant chemotherapy combined with radiotherapy in low-grade pituitary tumors","volume":"2022","author":"Cui","year":"2022","journal-title":"J Oncol"},{"key":"B237","article-title":"Transsphenoidal surgery for a life-threatening prolactinoma apoplexy during pregnancy","volume":"33","author":"Witek","year":"2012","journal-title":"Neuro Endocrinol Lett"},{"key":"B238","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s10143-023-02033-0","article-title":"Surgery as first-line treatment for prolactinoma? Discussion of the literature and results of a consecutive series of surgically treated patients","volume":"46","author":"Ottenhausen","year":"2023","journal-title":"Neurosurg Rev"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz144","article-title":"Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis","volume":"105","author":"Zamanipoor Najafabadi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B240","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11102-019-01016-z","article-title":"Surgery for prolactinomas: a better choice","volume":"23","author":"Honegger","year":"2020","journal-title":"Pituitary"},{"key":"B241","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/B978-0-12-804169-7.00016-7","article-title":"\u201cProlactinoma.,\u201d","volume-title":"The pituitary","author":"Chanson","year":"2017"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-016-2762-z","article-title":"Reasons and results of endoscopic surgery for prolactinomas: 142 surgical cases","volume":"158","author":"Akin","year":"2016","journal-title":"Acta Neurochir"},{"key":"B243","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1530\/EJE-10-0961","article-title":"Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: a single-center experience with 87 consecutive cases","volume":"164","author":"Qu","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-1000","article-title":"Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients","volume":"166","author":"Primeau","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-003-0134-y","article-title":"Microprolactinomas in males treated by transsphenoidal surgery","volume":"145","author":"Wolfsberger","year":"2003","journal-title":"Acta Neurochirurgica"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1177\/1179551420926181","article-title":"Clinical features, therapeutic trends, and outcome of giant prolactinomas: a single-center experience over a 12-year period","volume":"13","author":"Almalki","year":"2020","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"B247","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11102-011-0373-5","article-title":"First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment","volume":"15","author":"Baldari","year":"2012","journal-title":"Pituitary"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70728-8","article-title":"Temozolomide: a novel treatment for pituitary carcinoma","volume":"7","author":"Lim","year":"2006","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1338345\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T09:42:51Z","timestamp":1706866971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1338345\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,2]]},"references-count":248,"alternative-id":["10.3389\/fendo.2024.1338345"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1338345","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,2]]},"article-number":"1338345"}}